Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Aclidinium
Drug ID BADD_D02465
Description Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.
Indications and Usage Aclidinium bromide inhalation powder is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Marketing Status approved
ATC Code Not Available
DrugBank ID DB08897
KEGG ID Not Available
MeSH ID Not Available
PubChem ID 11434515
TTD Drug ID D0VP1V
NDC Product Code Not Available
UNII K17VY42F6C
Synonyms Not Available
Chemical Information
Molecular Formula C26H30NO4S2+
CAS Registry Number 727649-81-2
SMILES C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agitation17.02.05.012; 19.06.02.0010.001476%
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.0010.000434%-
Arrhythmia02.03.02.0010.000955%-
Asthma10.01.03.010; 22.03.01.0020.004861%-
Bronchospasm10.01.03.012; 22.03.01.0040.001823%
Bronchospasm paradoxical22.03.01.0060.000434%-
Cardiac failure02.05.01.001--
Chest discomfort02.02.02.009; 08.01.08.019; 22.12.02.0020.000955%-
Chest pain02.02.02.011; 08.01.08.002; 22.12.02.0030.000651%-
Chronic obstructive pulmonary disease22.03.01.0070.009853%-
Condition aggravated08.01.03.0040.001910%-
Confusional state17.02.03.005; 19.13.01.0010.003169%
Cough22.02.03.0010.003689%
Deafness04.02.01.0010.000434%-
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.0070.005295%
Drug ineffective08.06.01.006---
Dry mouth07.06.01.002--
Dysgeusia07.14.03.001; 17.02.07.0030.005165%
Dysphonia17.02.08.004; 19.19.03.002; 22.12.03.0060.002431%
Dyspnoea02.11.05.003; 22.02.01.0040.046573%
Dyspnoea exertional02.11.05.005; 22.02.01.0050.001172%-
Epistaxis22.04.03.001; 24.07.01.0050.000434%
Eye pain06.08.03.0020.000955%
Feeling abnormal08.01.09.0140.000434%-
Glossodynia07.14.02.0010.000955%-
Hypersensitivity10.01.03.0030.001302%
Hypertension24.08.02.0010.002214%
Hyperventilation19.01.02.004; 22.02.01.0060.000955%-
Hypoxia22.02.02.0030.000434%
Joint swelling15.01.02.0040.000955%-
The 1th Page    1 2 3    Next   Last    Total 3 Pages